%{search_type} search results

2,951 catalog results

RSS feed for this result
Book
1 online resource.
  • 1. Introduction of AMPs in the biological system including their norm and pathology 2. Regulation of AMPs expression in the digestive tract 3. The roles of antimicrobial peptides in the regulation of gastrointestinal microbiota and innate immunity 4. Inflammatory Bowel Disease Center, Division of Digestive Diseases 5. Antimicrobial peptides in the host-microbiota homeostasis 6. Antimicrobial peptides as potential therapy for gastrointestinal cancers: Opportunities and Challenges 7. Cathelicidin in gastrointestinal disorders 8. Modulation of immune functions by host defense peptides in the pathogenesis of colitis 9. AMPs and mechanisms of anti-microbial action.
  • (source: Nielsen Book Data)9780128143193 20180717
Antimicrobial peptides (AMPs), including cathelicidins and defensins are host defence peptides that carry out multiple roles in the gastrointestinal (GI) tract. Antimicrobial Peptides in Gastrointestinal Diseases presents knowledge about the physiological functions and pharmacological actions of AMPs in inflammation, cancer, and further infection of the GI tract. The book provides coverage from the basic research to clinical application for GI diseases. Current research and development of AMPs is presented, opening the way for further work on these peptides, not only in the context of GI diseases, but also for similar pathologies in other organs. AMPs are key to the regulation of human microbiome and second line defence in the GI mucosa, prevent colonization of pathogens and modulation of innate response to invading pathogens, and modify immunological reactions during inflammatory processes and oncogenic development in the GI mucosa. More importantly, AMPs possess diversified anti-microbial actions against various infectious diseases in the GI tract. With these physiological functions and pharmacological actions, AMPs have significant potential as therapeutic agents for the treatment of inflammation, cancer and further infection in the GI tract.
(source: Nielsen Book Data)9780128143193 20180717
Book
online resource (xxiv, 429 pages) ; 24 cm
Medical Library (Lane)
Book
online resource (xvi, 346 pages) : illustrations (some color).
This edited book is a compilation of findings on the molecular and cellular toxicity of nanoparticles (NPs) in animal cell, human cells, invertebrates. The varied selection of test models will provide better understanding about the horizon of NPs toxicity. Interaction of NPs with cells and its organelles can induce toxicological consequences, including transcriptional and translational alterations, DNA damage, cytotoxicity, oxidative stress, mitochondrial dysfunction and cell death. NPs can get internalized in cells through phagocytosis, macropinocytosis, receptor-mediated endocytosis and passive penetration, which can affect varied cell types. Readers will be benefited with the compilations on basic and molecular facet of NPs toxicity. The chapters will provide a comprehensive information on the state-of-the-art methodologies. The application of toxicogenomic approaches, which is already established in nanotoxicology, has been given special consideration to unravel the toxicodynamics of nanomaterials. Among these approaches, the high-throughput RNA sequencing (RNA-Seq), which is able to build a complete map of transcriptome across different cell types and perturbations upon NPs exposure has been included. The readers are also introduced to the less studied topic on the adsorption of biomolecules (mainly proteins) on the NPs surface, constituting the so-called “biomolecular corona”. The book has been designed for scientists engaged in NPs toxicity research. Nonetheless, it should be of interest to a variety of scientific disciplines including marine biology, environmental pollution, genetics, pharmacology, medicine, drug and food material sciences, consumer products. Also, the compilations will be of interest to the environmental watchdogs, federal regulators, risk assessors and the policy makers.
Medical Library (Lane)
Software/Multimedia
1 online resource (391 p.) : ill. (some col.)
"With the alarming increase in cancer diagnoses and genetic illnesses, traditional drug agents and their delivery media need to be re-evaluated to address a quickly evolving field. With newer smart materials for the controlled release of macromolecules, peptides, genetic material, etc. further complications arise, such as material performance, synthesis, functionalization and targeting, biological identity, and biocompatibility. The book provides a comprehensive overview of the recent developments on "smart" targeting and drug delivery systems with a variety of carriers like nanoparticles, membranes, and hydrogels. It contains detailed descriptions on the recent trends in this field in the ongoing battle with catastrophic diseases like cancer. This field of research has been in its infancy and continues to face growth, and with it, further challenges and difficulties along the way toward maturity, which are accurately introduced in this book."-- Provided by publisher.
Book
xii, 495 pages ; 28 cm
  • PART I: Drug Discovery and Development 1. Historical Perspective and Overview of Drug Discovery 2. Drug discovery: Hit and Lead Discovery 3. Drug Discovery: Optimization of Lead Properties PART II: Classes of Drug Targets 4. Medicinal Chemistry Strategies Used in Lead Optimization 5. The Process of Developing a Drug from an Optimized Lead 6. Receptors as Drug Targets 7. Enzymes as Drug Targets 8. Protein-Protein Interactions and Lipids as Drug Targets 9. DNA and RNA as Drug Targets PART III: Selected Therapeutic Areas 10. Anti-Cancer Drugs 11. Infectious Diseases I: Antiviral and Antifungal Drugs 12. Infectious Diseases II: Antibacterial and Antiparasitic Drugs 13. Drugs Acting on the CNS.
  • (source: Nielsen Book Data)9780815345565 20180702
Medicinal Chemistry teaches essential concepts by focusing on how the field is actually practiced, melding real-world research experience with basic principles and modern methods. Written by practicing medicinal chemists, this textbook is intended for advanced undergraduates and first-year graduate students in biology, chemistry, and biochemistry. Pre-medical or pre-pharmacy students and professionals entering the drug discovery field will also find it a useful reference. Building on a foundation of synthetic organic chemistry and structural biology, the book interweaves therapeutics, case studies, historical context, and techniques for discovering, developing, and optimizing new drugs. Chapters are richly illustrated and include problems and annotated journal references with accompanying exercises and answers.
(source: Nielsen Book Data)9780815345565 20180702
Science Library (Li and Ma)
Book
1 online resource.
Book
online resource (xv, 312 pages) : illustrations (chiefly color)
  • Traditional medicine : the ancient roots of modern practice
  • Are medicinal plants effective for skin cancer?
  • Fighting the inevitable : skin aging and plants
  • Exploiting medicinal plants as possible treatments for acne vulgaris
  • Medicinal plants as alternative treatments for progressive macular hypomelanosis
  • The role of medicinal plants in oral care
  • Can medicinal plants provide an adjuvant for tuberculosis patients?
  • Medicinal plants used in the treatment of superficial skin infections : from traditional medicine to herbal soap formulations
  • Garlic (Allium sativum) and its associated molecules, as medicine
  • Maximizing medicinal plants : steps to realizing their full potential.
"Medicinal Plants for Holistic Health and Well-Being discusses, in depth, the use of South African plants to treat a variety of ailments, including tuberculosis, cancer, periodontal diseases, acne, postmacular hypomelanosis, and more. Plants were selected on the basis of their traditional use, and the book details the scientific evidence that supports their pharmacological and therapeutic potential to safely and effectively treat each disease. Thus, this book is a valuable resource for all researchers, students and professors involved in advancing global medicinal plant research." --Publisher.
Medical Library (Lane)
Book
xlii, 546 pages : illustrations (some color) ; 25 cm.
"Volume 18, entitled Metallo-Drugs: Development and Action of Anticancer Agents of the series Metal Ions in Life Sciences centers on biological, medicinal inorganic chemistry. The serendipitous discovery of the antitumor activity of cis-diamminodichloroplatinum(II) (cisplatin) by Barnett Rosenberg in the 1960s is a landmark in metallodrug-based chemotherapy. The success of cisplatin in the clinic, followed by oxaliplatin and carboplatin, along with their drawbacks relating mainly to resistance development and severe toxicity, initiated research on polynuclear platinum complexes and on Pt(IV) complexes as prodrugs. Furthermore, the indicated shortcomings led to the exploration of other transition and main group metal ions, among them Ru(II/III), Au(I/III), Ti(IV), V(IV/V), and Ga(III) including also the essential metal ions Fe(II/III), Cu(I/II), and Zn(II). Ionic as well as covalent and non-covalent interactions between structurally very different complexes and biomolecules like nucleic acids, proteins, and carbohydrates are studied and discussed with regard to their possible anticancer actions. Hence, MILS-18 summarizes the research at the forefront of medicinal inorganic chemistry, including studies on the next-generation, tailor-made anticancer drugs. All this and more is treated in an authoritative and timely manner in the 17 stimulating chapters of this book, written by 39 internationally recognized experts from 10 nations (from the US via Europe to China and Australia). The impact of this vibrant research area is manifested by more than 2700 references, nearly 150 illustrations (more than half in color) and several comprehensive tables. Metallo-Drugs: Development and Action of Anticancer Agents is an essential resource for scientists working in the wide range from enzymology, material sciences, analytical, organic, and inorganic biochemistry all the way through to medicine including the clinic ... not forgetting that it also provides excellent information for teaching"--Provided by publisher.
Science Library (Li and Ma)
Book
1 online resource.
  • 1. Introduction of Mid-Size Drugs and Peptidomimetics.- 2. Chloroalkene Dipeptide Isosteres as Peptidomimetics.- 3. Conformational-restricted Cyclic Peptides.- 4. Peptidomimetics that Mimic Secondary Structures of Peptides.- 5.Peptidomimetics that Mimic Tertiary Structures of Peptides.- 6. Conjugated Compounds Involving Peptides.- 7. Summary and Future Perspectives of Researches on Mid-Size Drugs.
  • (source: Nielsen Book Data)9789811076909 20180430
This brief describes studies conducted by the authors on mid-size drugs utilizing peptides and peptidomimetics, and on the development of anti-HIV agents. Peptides are important biological molecules and have various physiological actions. Peptide-based drug discovery may help bring about the development of useful medicines that are highly safe and show potent pharmacological effects in small doses. Recently, it has been shown that there is an important drug-like space in the mid-sized region between low- and high-molecular-weight compounds. Thus, mid-size drugs such as peptide compounds are being focused on. To date, several peptidomimetics that mimic primary, secondary, and tertiary structures of peptides have been developed to maintain and improve biological activities and actions of peptides. In this book, the features and advantages of mid-size drugs are described in detail. In addition, the merits of utilizing peptidomimetics in the development of mid-size drugs are referred to. Understanding such peptide-derived mid-size drugs will lead to a comprehensive expansion of medicinal chemistry.
(source: Nielsen Book Data)9789811076909 20180430
Book
pages ; [ca. 23-29] cm
  • Pharmacotherapy, Toxicodynamics and Regulatory Science-Divergent Objectives Nonclinical Pharmacokinetics - a primer Routes - with considerations for species specificity Delivery Systems Regimens Fundamentals of Nonclinical Formulation Excipients and Vehicles: Tolerance and toxicity Appendices.
  • (source: Nielsen Book Data)9781466502536 20171218
If we will ever achieve Paul Ehrlich's "magic bullet, " that is, a molecule which goes with high selectivity to the therapeutic target site, does what it needs to do, and is subsequently cleared from the body, the practice of safety assessment will have to change. Nonclinical Drug Administration: Formulations, Routes and Regimens for Solving Drug Delivery Problems in Animal Model Systems seeks to address a trio of objectives that, though separate, are linked and central to biomedical science and, ultimately, medicine. Rather seeing these as separate "silos, " those working in nonclinical safety assessment will have to view these three in an integrated manner and to regularly and thoughtfully incorporate new information and technology. The trio of objectives this book explores are: first, to present how to deliver more of a drug product systemically to facilitate the regulatory need for evaluating safety and efficacy in animal species (at elevated exposure levels) prior to advancing the drug to human testing; second is to achieve better tolerance to therapeutics administration in test animals and humans which achieves objectives 1 and 3; and third, to explore ways to improve on therapeutic target receptor delivery performance, therefore improving both clinical pharmacodynamics bioavailability and specificity. The book's ten chapters assemble the basic concepts, principles and hypotheses involved in quantitative receptor and chronological organism interaction dynamics central to the successful development of new therapeutics which depend on systemic administration to achieve desired therapeutic goals and in so doing avoid outcomes which limit, marginalize, or preclude the therapeutic use of so many molecules.
(source: Nielsen Book Data)9781466502536 20171218
The concept of the perfect medicine as a molecule that goes with high selectivity to the therapeutic target site, does what it needs to do, and is subsequently cleared from the body is especially relevant now. Much of the current costs and post-market safety concerns arise from the inability to achieve adequate concentrations and selectivity in the due course of actually delivering the active drug. Providing an integrated approach, this book presents ways of achieving the desired adequate and selective delivery using the currently available technology in three tool sets: route, regimen, and formulation.
(source: Nielsen Book Data)9781466502598 20171218
Book
200 pages : color illustrations, color maps, charts ; 24 cm
  • Dédicaces et remerciements -- Préface -- Avant-propos -- Contexte biogéographique -- Les difficultés et contraintes de la gestion des plantes médicinales -- Situation de l'étude -- Le degré d'alerte -- L'environnement social -- Le potentiel de la biodiversité du Sénégal -- Méthodologie -- Résultats -- Intérêt et limites de l'étude -- La diversité culturelle est la base de la diversité biologique -- Les savoirs locaux -- Quelle valeur donner aux savoirs locaux pour une gestion durable des plantes médicinales ? -- Caractérisation des tradipraticiens -- Pathologies -- Périodes de récolte -- Techniques de coupe, de conditionnement et les mesures conservatoires préconisées pour une gestion durable des plantes médicinales -- La Formation des acteurs -- La mise en place d'un cadre de collaboration entre les associations des herboristes, des tradipraticiens, des ONG et la DEFCCS -- Quantités de plantes médicinales exploitées durant les quatre dernières années (2005 à 2008) -- Valorisation des plantes médicinales par une politique d'harmonisation du contrôle de la commercialisation -- Recommandations -- Conclusion -- Liste de quelques plantes médicinales ayant complètement disparu dans huit régions du Sénégal -- Liste des acronymes -- Bibliographie -- Note sur l'auteur.
"Cet ouvrage est le fruit de trente-trois années de recherche sur les plantes médicinales et les savoirs locaux. Colonel Papa Momar Faye nous y invite à mieux connaître les plantes médicinales récoltées par les herboristes et leur degré de protection. On y retrouve également une cartographie des sites des tradipraticiens sérieux et compétents. Cet ouvrage permet par ailleurs d'alerter sur les menaces qui pèsent sur les plantes médicinales et de sensibiliser les autorités, les bailleurs sur les pressions subies par les plantes médicinales. Enfin l'auteur propose des solutions pour une meilleure conservation et gestion de ces ressources."--Page 4 of cover.
Green Library
Book
1 online resource (xiv, 465 pages) : illustrations (some color). Digital: text file; PDF.
  • 1. Conformational Properties of hIAPP22-29 (NFGAILSS) and Rational Drug Design Panagiotis Lagarias, Youness Elkhou, Jason Vedad, Adam Profit, Tahsin F. Kellici, Antonios Kolocouris, Ruel Desamero, and Thomas Mavromoustakos 2. Electronic and Electrostatic Approaches to the Development of Peptide-based Inhibitors of Amylin Aggregation Adam A. Profit and Ruel Z. B. Desamero 3. In Silico Drug Design: Applications of non-peptide mimetics towards the Immunotherapy of Multiple Sclerosis Haralambos Tzoupis and Theodore Tselios 4. Binding Moiety Mapping by Saturation Transfer Difference NMR Jeffrey R. Brender, Janarthanan Krishnamoorthy, Anirban Ghosh, and Anirban Bhunia 5. Protein Ligand Docking in Drug Design: Performance Assessment and Binding-Pose Selection Flavio Ballante 6. Rational Drug Design using Integrative Structural Biology Magda S. Chegkazi, Michael Mamais, Anastasia I. Sotiropoulou, and Evangelia D. Chrysina 7. Enalos+Knime Nodes: New Cheminformatics Tools for Drug Discovery Dimitra-Danai Varsou, Spyridon Nikolakopoulos, Andreas Tsoumanis, Georgia Melagraki, and Antreas Afantitis 8. Bioguided Design of Trypanosomicidal Compounds: A Successful Strategy in Drug Discovery Guzman Ignacio Alvarez Touron 9. A Hybrid Virtual Screening Protocol Based on Binding Mode Similarity Andrew Anighoro and Jurgen Bajorath 10. Single Step Determination of Unlabelled Compound Kinetics Using a Competition Association Binding Method Employing Time-resolved FRET David A. Sykes and Steven J. Charlton 11. Dynamic Undocking: A Novel Method for Structure-based Drug Discovery Maciej Majewski, Sergio Ruiz-Carmona, and Xavier Barril 12. The impact of Lipophilicity in Drug Discovery - Rapid Measurements by Means of Reversed Phase HPLC Constantinos Giaginis, Fotios Tsopelas, and Anna Tsantili-Kakoulidou 13. Exploring Polypharmacology in Drug Design Patricia Saenz-Mendez and Leif A. Eriksson 14. Development of Nuclear Receptor Modulators Simone Schierle and Daniel Merk 15. In silico Screening of Compound Libraries using a Consensus of Orthogonal Methodologies Vassilios Myrianthopoulos, Georgios Lamprinidis and Emmanuel Mikros 16. Insights in Organometallic Synthesis of Various Adamantane Derivatives with Sigma Receptor ( R) Binding Affinity and Antiproliferative / Anticancer Activity Ioannis Papanastasiou 17. Supervised Molecular Dynamics (SuMD) Approaches in Drug Design Davide Sabbadin, Veronica Salmaso, Mattia Sturlese, and Stefano Moro 18. Lead Identification through the Synergistic Action of Biomolecular NMR and in Silico Methodologies Konstantinos D. Marousis, Aikaterini C. Tsika, Maria Birkou, Minos-Timotheos Matsoukas, and Georgios A. Spyroulias 19. The use of Dynamic Pharmacophore in Computer Aided Hit Discovery: A Case Study Ugo Perricone, Marcus Wieder, Thomas Seidel, Thierry Langer, and Alessandro Padova 20. Rational Design of MAGL inhibitors Carlotta Granchi, Flavio Rizzolio, Isabella Caligiuri, Marco Macchia, Adriano Martinelli, Filippo Minutolo, and Tiziano Tuccinardi 21. Application of Virtual Screening Approaches for the Identification of Small Molecule Inhibitors of the Methyllysine Reader Protein Spindlin1 Chiara Luise and Dina Robaa 22. Designing Natural Product Hybrids Bearing Triple Antiplatelet Profile and Enhanced Human Plasma Stability Antonis Tsiailanis, Maria Tsoumani, Evgenios Stylos, Maria V. Chatziathanasiadou, Tahsin Kellici, Thomas Mavromoustakos, Alexandros D. Tselepis, and Andreas G. Tzakos 23. Pharmacophore Generation and 3D-QSAR Model Development using PHASE Eleni Vrontaki and Antonios Kolokouris 24. Design of Drugs by Filtering through ADMET, Physicochemical, and Ligand-Target Flexibility Properties Marlet Martinez-Archundia, Martiniano Bello, and Jose Correa-Basurto 25. Reactions in NMR tubes as Key Weapon in Rational Drug Design Dimitrios Ntountaniotis 26. Application of Multiscale Simulations Tools on GPCRs. An Example with Angiotensin-II type 1 Receptor Ismail Erol, Busecan Aksoydan, Isik Kantarcioglu, and Serdar Durdagi 27. Angiotensin II Type 1 Receptor Homology Models: A Comparison between In Silico and the Crystal Structures Tahsin F. Kellici.
  • (source: Nielsen Book Data)9781493986293 20180910
This volume covers several aspects of rational drug design, such as synthesis of novel bioactive drugs; development and application of new methodologies; computational methods valuable for the establishment of new approaches in drug discovery; and the effects of physical-chemical and ADMET properties of the designed potential drugs. Chapters guide readers through amyloid deposits, Saturation Transfer Difference (STD) NMR, methods on bioguided design, the importance of lipophilicity in drug design, ADMET, FRET, structural biology, and homology modeling. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Rational Drug Design: Methods and Protocols aims to ensure successful results in the further study of this vital field.
(source: Nielsen Book Data)9781493986293 20180910
Book
1 online resource.
Social and Administrative Aspects of Pharmacy in Low- and Middle-Income Countries: Present Challenges and Future Solutions examines the particularities of low- and middle-income countries and offers solutions based on their needs, culture and available resources. Drawing from the firsthand experience of researchers and practitioners working in these countries, this book addresses the socio-behavioral aspects of pharmacy and health, pharmacoeconomics, pharmaceutical policy, supply management and marketing, pharmacoepidemiology and public health pharmacy specific to low- and middle-income countries. While some practices may be applied appropriately in disparate places, too often pharmacy practice in low- and middle-income countries is directly copied from successes in developed countries, despite the unique needs and challenges low- and middle-income countries face.
Book
1 online resource.
  • 1. Significance of medicinal plants in human life 2. Drug synthesis from natural products: A historical overview and future perspective 3. Substituting medicinal plants through drug synthesis 4. Bioactive Constituents of Neem 5. Turmeric: Isolation and synthesis of important biological molecules 6. Properties and important molecules of medicinal interest in wood apple (Aegle marmelos) 7. Medicinally important constituents of Tulsi (Ocimum spp.) 8. Biological importance of Aloe vera and its active constituents 9. Alkaloid group of Cinchona officinalis: Structural, synthetic and medicinal aspects 10. Isolation of medicinally important constituents from rare and exotic medicinal plants 11. Medicinal properties of marine plants 12. Ayurveda: A new dimension in the era of modern medicine 13. Dual role of drugs: Beneficial and harmful aspects 14. Introduction to medicinally important constituents from Chinese medicinal plants.
  • (source: Nielsen Book Data)9780081020715 20180611
Synthesis of Medicinal Agents from Plants highlights the importance of synthesizing medicinal agents from plants and outlines methods for performing it effectively. Beginning with an introduction to the significance of medicinal plants, the book goes on to provide a historical overview of drug synthesis before exploring how this can be used to successfully replicate and adapt the active agents from natural sources. Chapters then explore the medicinal properties of a number of important plants, before concluding with a discussion of the future of drugs from medicinal plants. Illustrated with real-world examples, it is a practical resource for researchers in this field. In an age of rapid environmental destruction, hundreds of medicinal plants are at risk of extinction from overexploitation and deforestation, limiting the natural resources available for active agent extraction, thereby threatening the discovery of future cures for diseases. Simultaneously, with the increasing population and advances in medical sciences, the demand for drugs is continuously increasing and cannot be met with just plants. The ability to synthetically replicate the active compounds from these plants is essential in creating an ecologically-aware, sustainable future for drug design.
(source: Nielsen Book Data)9780081020715 20180611
Book
1 online resource (xvi, 294 pages) : illustrations (some color). Digital: text file; PDF.
  • Optocapacitance allows for photostimulation of neurons without requiring genetic modification / Joao L. Carvalho-de-Souza, Jeremy S. Treger, David R. Pepperberg, and Francisco Bezanilla
  • Nanoparticle-assisted localized optical stimulation of cultured neurons / Flavie Lavoie-Cardinal, Charleen Salesse, Pierre-Luc Ayotte-Nadeau, and Paul De Koninck
  • Stimulation of primary auditory neurons mediated by near-infrared excitation of gold nanorods / Chiara Paviolo, Karina Needham, William G.A. Brown, Jiawey Yong, and Paul R. Stoddart
  • Nanoparticle preparation for magnetothermal genetic stimulation in cell culture and in the brain of live rodents / Idoia Castellanos-Rubio, Rahul Munshi, Shahnaz Qadri, and Arnd Pralle
  • Genetically encoded nanoparticles for neural modulation / Sarah A. Stanley
  • Two applications of gold nanostars to hippocampal neuronal cells : localized photothermal ablation and stimulation of firing rate / Fidel Santamaria and Xomalin G. Peralta
  • Regulating growth cone motility and axon growth by manipulating targeted superparamagnetic nanoparticles / Tanchen Ren, Jeffrey L. Goldberg, and Michael B. Steketee
  • Assessment of the effects of a wireless neural stimulation mediated by piezoelectric nanoparticles / Attilio Marino, Satoshi Arai, Yanyan Hou, Mario Pellegrino, Barbara Mazzolai, Virgilio Mattoli, Madoka Suzuki, and Gianni Ciofani
  • Influence of external electrical stimulation on cellular uptake of gold nanoparticles / Samantha K. Franklin, Brandy Vincent, Sumeyra Tek, and Kelly L. Nash
  • Estimating the effects of nanoparticles on neuronal field potentials based on their effects on single neurons in vitro / Michael Busse, Narsis Salafzoon, Annette Kraegeloh, David R. Stevens, and Daniel J. Strauss
  • Application of in vivo extracellular recording technique to study the biological effects of nanoparticles in brain / Yanyan Miao, Han Zhao, Jutao Chen, Ming Wang, and Longping Wen
  • Using the whole cell patch clamp technique to study the effect of nanoparticles in hippocampal neurons / Xiaochen Zhang and Zhuo Yang
  • Comparative analysis of neurotoxic potential of synthesized, native, and physiological nanoparticles / Arsenii Borysov, Natalia Pozdnyakova, Artem Pastukhov, and Tatiana Borisova
  • Stoichiometrically defined neural coculture model to screen nanoparticles for neurological applications / Stuart I. Jenkins and Divya M. Chari
  • Long-term organism distribution of microwave hydrothermally synthesized ZrO2 : Pr nanoparticles / Jarosław Kaszewski, Paula Kiełbik, Anna Słońska-Zielonka, Izabela Serafińska, Jakub Nojszewski, Marek Godlewski, Zdzisław Gajewski, and Michał M. Godlewski
  • Gold nanoparticles as nucleation centers for amyloid fibrillation / Yanina D. Álvarez, Jesica V. Pellegrotti, and Fernando D. Stefani.
This volume discusses techniques to synthesize and functionalize nanoparticles, monitor their delivery and uptake, and identify and evaluate their lethal and non-lethal effects on the metabolic activity of the nervous system. The chapters in this book are divided into 4 sections: photo-stimulation, thermal stimulation, mechanical perturbation, and toxicity and physiological effects. The first 3 sections focus on nanoparticle interactions with external sources that disturb the neuronal system, while the 4th explores the effects of having nanoparticles in a neuronal system in the absence of external stimuli. In Neuromethods series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory. Cutting-edge and comprehensive, Use of Nanoparticles in Neuroscience is a valuable resource for graduate students and specialized researchers that want to learn techniques needed to quantify experiments that use nanoparticles in the nervous system.
(source: Nielsen Book Data)9781493975822 20180312
Book
online resource (xxxiv, 521 pages) : illustrations
  • Typical antibody-drug conjugates / John Lambert
  • Selecting optimal ADC targets using indication-dependent or indication-independent approaches / Robert Hollingsworth and Jay Harper
  • Antibody drug conjugates : an overview of the CMC and characterization process / Janet Wolfe and Phillip Ross
  • Linker and conjugation technology and improvements / Riley Ennis and Sourav Sinha
  • Formulation and stability / Kouhei Tsumoto, Anthony Young, and Satoshi Ohtake
  • QC assay development / Xiao-Hong Chen and Mate Tolnay
  • Occupational health and safety aspects of ADCs and their toxic payloads / Robert Sussman and John Farris
  • Bioanalytical strategies enabling successful ADC translation / Xiaogang Han, Lindsay King, and Steve Hansel
  • Nonclinical pharmacology and mechanistic modeling of antibody drug conjugates in support of human clinical trials / Brian J. Schmidt, Chin Pan, Heather E. Vezina, Huadong Sun, Douglas D. Leipold, and Manish Gupta
  • Pharmacokinetics of antibody-drug conjugates / Amrita Kamath
  • Path to market approval : regulatory perspective of ADC nonclinical safety assessments / Stacey Ricci and Natalie Simpson
  • Antibody drug conjugates : clinical strategies and applications / Heather E. Vezina, Lucy Lee, Brian J. Schmidt, Manish Gupta
  • Antibody-drug conjugates (ADCs) in clinical development / Patricia LoRusso and Joseph McLaughlin
  • ADCs approved for use : Trastuzumab emtansine (Kadcyla, T-DM1) in patients with previously treated HER2-positive metastatic breast cancer / Gail Lewis Phillips, Sanne de Hass, Sandhya Girish, and Ellie Guardino
  • ADCs approved for use : Brentuximab Vedotin / Sven DeVos and Monica Mead
  • Radioimmunotherapy / Jeffrey Wong and Savita Dandapani
  • Radiolabeled antibody-based imaging in clinical oncology / Bart Hendriks and Daniel Gaddy
  • Antibody-drug conjugates : the next evolution in the cure for cancer
  • William C. Olson and Amy Q. Han.
Medical Library (Lane)
Book
1 online resource.
  • Typical antibody-drug conjugates / John Lambert
  • Selecting optimal ADC targets using indication-dependent or indication-independent approaches / Robert Hollingsworth and Jay Harper
  • Antibody drug conjugates : an overview of the CMC and characterization process / Janet Wolfe and Phillip Ross
  • Linker and conjugation technology and improvements / Riley Ennis and Sourav Sinha
  • Formulation and stability / Kouhei Tsumoto, Anthony Young, and Satoshi Ohtake
  • QC assay development / Xiao-Hong Chen and Mate Tolnay
  • Occupational health and safety aspects of ADCs and their toxic payloads / Robert Sussman and John Farris
  • Bioanalytical strategies enabling successful ADC translation / Xiaogang Han, Lindsay King, and Steve Hansel
  • Nonclinical pharmacology and mechanistic modeling of antibody drug conjugates in support of human clinical trials / Brian J. Schmidt, Chin Pan, Heather E. Vezina, Huadong Sun, Douglas D. Leipold, and Manish Gupta
  • Pharmacokinetics of antibody-drug conjugates / Amrita Kamath
  • Path to market approval : regulatory perspective of ADC nonclinical safety assessments / Stacey Ricci and Natalie Simpson
  • Antibody drug conjugates : clinical strategies and applications / Heather E. Vezina, Lucy Lee, Brian J. Schmidt, Manish Gupta
  • Antibody-drug conjugates (ADCs) in clinical development / Patricia LoRusso and Joseph McLaughlin
  • ADCs approved for use : Trastuzumab emtansine (Kadcyla, T-DM1) in patients with previously treated HER2-positive metastatic breast cancer / Gail Lewis Phillips, Sanne de Hass, Sandhya Girish, and Ellie Guardino
  • ADCs approved for use : Brentuximab Vedotin / Sven DeVos and Monica Mead
  • Radioimmunotherapy / Jeffrey Wong and Savita Dandapani
  • Radiolabeled antibody-based imaging in clinical oncology / Bart Hendriks and Daniel Gaddy
  • Antibody-drug conjugates : the next evolution in the cure for cancer
  • William C. Olson and Amy Q. Han.
Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells. Discusses the basics, drug delivery strategies, pharmacology and toxicology, and regulatory approval strategies Covers the conduct and design of oncology clinical trials and the use of ADCs for tumor imaging Includes case studies of ADCs in oncology drug development Features contributions from highly-regarded experts on the frontlines of ADC research and development.
(source: Nielsen Book Data)9781119060680 20180709
Book
1 online resource (566 pages) : color illustrations
  • Typical antibody-drug conjugates / John Lambert
  • Selecting optimal ADC targets using indication-dependent or indication-independent approaches / Robert Hollingsworth and Jay Harper
  • Antibody drug conjugates : an overview of the CMC and characterization process / Janet Wolfe and Phillip Ross
  • Linker and conjugation technology and improvements / Riley Ennis and Sourav Sinha
  • Formulation and stability / Kouhei Tsumoto, Anthony Young, and Satoshi Ohtake
  • QC assay development / Xiao-Hong Chen and Mate Tolnay
  • Occupational health and safety aspects of ADCs and their toxic payloads / Robert Sussman and John Farris
  • Bioanalytical strategies enabling successful ADC translation / Xiaogang Han, Lindsay King, and Steve Hansel
  • Nonclinical pharmacology and mechanistic modeling of antibody drug conjugates in support of human clinical trials / Brian J. Schmidt, Chin Pan, Heather E. Vezina, Huadong Sun, Douglas D. Leipold, and Manish Gupta
  • Pharmacokinetics of antibody-drug conjugates / Amrita Kamath
  • Path to market approval : regulatory perspective of ADC nonclinical safety assessments / Stacey Ricci and Natalie Simpson
  • Antibody drug conjugates : clinical strategies and applications / Heather E. Vezina, Lucy Lee, Brian J. Schmidt, Manish Gupta
  • Antibody-drug conjugates (ADCs) in clinical development / Patricia LoRusso and Joseph McLaughlin
  • ADCs approved for use : Trastuzumab emtansine (Kadcyla, T-DM1) in patients with previously treated HER2-positive metastatic breast cancer / Gail Lewis Phillips, Sanne de Hass, Sandhya Girish, and Ellie Guardino
  • ADCs approved for use : Brentuximab Vedotin / Sven DeVos and Monica Mead
  • Radioimmunotherapy / Jeffrey Wong and Savita Dandapani
  • Radiolabeled antibody-based imaging in clinical oncology / Bart Hendriks and Daniel Gaddy
  • Antibody-drug conjugates : the next evolution in the cure for cancer
  • William C. Olson and Amy Q. Han.
Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells. Discusses the basics, drug delivery strategies, pharmacology and toxicology, and regulatory approval strategies Covers the conduct and design of oncology clinical trials and the use of ADCs for tumor imaging Includes case studies of ADCs in oncology drug development Features contributions from highly-regarded experts on the frontlines of ADC research and development.
(source: Nielsen Book Data)9781119060680 20180709
Book
1 online resource (xvii, 291 pages)
  • List of Contributors 1. IntroductionDonald Huddler 2. Thermodynamics in Drug DiscoveryOBrienMarkova&Holdgate 3. Tailoring Hit Identification and Qualification Methods for Targeting Protein-Protein InteractionsBjorn Walse, Andrew P. Turnbull, Susan M. Boyd 4. HYDROGEN DEUTERIUM EXCHANGE MASS SPECTROMETRY IN DRUG DISCOVERYThorleif Lavold, Roman Zubarev and Juan Astorga-Wells 5. MICROSCALE THERMOPHORESIS IN DRUG DISCOVERYTanja Bartoschik, Melanie Maschberger, Alessandra Feoli, Timon Andre, Philipp Baaske, Stefan Duhr and Dennis Breitsprecher 6. SPR Screening Applying the new generation of SPR hardwareKartik Narayan and Steve Carroll 7. Weak Affinity Chromatography (WAC)Sten Ohlsonâ and Minh-Dao Duong-Thi 8. 1D NMR Methods for Hit IdentificationMary J Harner, Guille Metzler, Caroline A Fanslau, Luciano Mueller, William J Metzler 9. Protein-Based NMR Methods Applied to Drug DiscoveryAlessio Bortoluzzi, Alessio Ciulli 10. Applications of Ligand and Protein-observed NMR in DiscoveryIsabelle Krimm Conclusion 11. Using Biophysical Methods to Optimize Compound Residence TimeG. A. Holdgate, P. Rawlins, M. Bista, C. J. Stubbs 12. Applying biophysical and biochemical methods to the discovery of allosteric modulators of the AAA ATPase p97Stacie L. Bulfer and Michelle R. Arkin 13. Driving Drug Discovery with Biophysical Information Application to Staphylococcus aureus Dihydrofolate Reductase (DHFR)Parag Sahasrabudhe, Veerabahu Shanmugasundaram, Mark Flanagan, Kris A. Borzilleri, Holly Heaslet, Anil Rane, Alex McColl, Tim Subashi, George Karam, Ron Sarver, Melissa Harris, Boris A. Chrunyk, Chakrapani Subramanyam, Thomas V. Magee, Kelly Fahnoe, Brian Lacey, Henry Putz, J. Richard Miller, Jaehyun Cho, Arthur Palmer III and Jane M. Withka 14. Assembly of fragment screening libraries: Property and diversity analysisBradley C. Doak, Craig J. Morton, Jamie S. Simpson & Martin J. Scanlon Index.
  • (source: Nielsen Book Data)9781119099482 20170731
Applied Biophysics for Drug Discovery is a guide to new techniques and approaches to identifying and characterizing small molecules in early drug discovery. Biophysical methods are reasserting their utility in drug discovery and through a combination of the rise of fragment-based drug discovery and an increased focus on more nuanced characterisation of small molecule binding, these methods are playing an increasing role in discovery campaigns. This text emphasizes practical considerations for selecting and deploying core biophysical method, including but not limited to ITC, SPR, and both ligand-detected and protein-detected NMR. Topics covered include: Design considerations in biophysical-based lead screening Thermodynamic characterization of protein-compound interactions Characterizing targets and screening reagents with HDX-MS Microscale thermophoresis methods (MST) Screening with Weak Affinity Chromatography Methods to assess compound residence time 1D-NMR methods for hit identification Protein-based NMR methods for SAR development Industry case studies integrating multiple biophysical methods This text is ideal for academic investigators and industry scientists planning hit characterization campaigns or designing and optimizing screening strategies.
(source: Nielsen Book Data)9781119099482 20170731
Book
online resource (xvii, 291 pages) ; 25 cm
  • Introduction
  • Thermodynamics in drug discovery
  • Tailoring hit identification and qualification methods for targeting protein-protein interactions
  • Hydrogen-deuterium exchange mass spectrometry in drug discovery - theory, practice and future
  • Microscale thermophoresis in drug discovery
  • SPR screening: applying the new generation of SPR hardware
  • Weak affinity chromatography (WAC)
  • 1D NMR methods for hit identification
  • Protein-based NMR methods applied to drug discovery
  • Applications of ligand and protein-observed NMR in ligand discovery
  • Using biophysical methods to optimize compound residence time
  • Applying biophysical and biochemical methods to the discovery of allosteric modulators of the AAA ATPase p97
  • Driving drug discovery with biophysical information: application to Staphylococcus aureus Dihydrofolate reductase (DHFR)
  • Assembly of fragment screening libraries: property and diversity analysis.
"This book is a guide to new techniques and approaches to identifying and characterizing small molecules in early drug discovery. Biophysical methods are reasserting their utility in drug discovery and through a combination of the rise of fragment-based drug discovery and an increased focus on more nuanced characterisation of small molecule binding, these methods are playing an increasing role in discovery campaigns"--Provided by publisher.
Medical Library (Lane)